HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alexa P Kollmeier Selected Research

Interleukin-23 Subunit p19

1/2021Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
1/2020Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
1/2020Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alexa P Kollmeier Research Topics

Disease

13Psoriatic Arthritis
11/2022 - 01/2020
5Infections
01/2022 - 01/2020
3Fatigue
11/2022 - 01/2021
3Psoriasis (Pustulosis Palmaris et Plantaris)
01/2022 - 12/2021
2Chronic Disease (Chronic Diseases)
01/2022 - 01/2021
2Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
12/2021 - 01/2021
2Opportunistic Infections (Opportunistic Infection)
12/2021 - 01/2021
1Pain (Aches)
11/2022
1Arthritis (Polyarthritis)
01/2022
1Tuberculosis (Tuberculoses)
12/2021
1Injection Site Reaction
12/2021
1Neoplasms (Cancer)
12/2021
1Uveitis
12/2021
1Necrosis
01/2021
1Heart Failure
01/2020
1Asthma (Bronchial Asthma)
11/2018
1Type 2 Diabetes Mellitus (MODY)
11/2009
1Anaphylaxis (Anaphylactic Shock)
10/2004

Drug/Important Bio-Agent (IBA)

13guselkumabIBA
11/2022 - 01/2020
6Monoclonal AntibodiesIBA
08/2022 - 01/2020
5Biological ProductsIBA
01/2022 - 01/2020
4C-Reactive ProteinIBA
01/2021 - 01/2020
3Interleukin-23 (Interleukin 23)IBA
01/2022 - 01/2020
3Interleukin-23 Subunit p19IBA
01/2021 - 01/2020
2Biomarkers (Surrogate Marker)IBA
08/2022 - 08/2022
2CollagenIBA
08/2022 - 08/2022
2InterleukinsIBA
01/2022 - 12/2021
2Immunoglobulin A (IgA)IBA
01/2022 - 01/2022
2Antirheumatic Agents (DMARD)IBA
01/2022 - 01/2020
1AntibodiesIBA
12/2021
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2020
1Tumor Necrosis Factor InhibitorsIBA
01/2020
1apremilastIBA
01/2020
1CytokinesIBA
01/2020
1toreforantIBA
11/2018
1Histamine H4 ReceptorsIBA
11/2018
1Histamine (Histamine Dihydrochloride)FDA Link
11/2018
1Insulin Lispro (Humalog)FDA Link
11/2009
1Insulin Detemir (Levemir)FDA Link
11/2009
1SuspensionsIBA
11/2009
1Insulin Glargine (Lantus)FDA Link
11/2009
1Protamines (Protamine Sulfate)FDA Link
11/2009
1Pantoprazole (Protonix)FDA LinkGeneric
10/2004

Therapy/Procedure

4Therapeutics
01/2022 - 01/2020